Icosavax Quarterly Balance Sheets Chart
Quarterly
|
Annual
Icosavax Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||
| current assets: | ||||||||||
| cash and cash equivalents | 63,239,000 | 155,073,000 | 49,341,000 | 58,846,000 | 64,505,000 | 108,345,000 | ||||
| restricted cash | 1,061,000 | 1,061,000 | 1,061,000 | 1,061,000 | 1,061,000 | 1,642,000 | 2,652,000 | 1,179,000 | ||
| short-term investments | 165,967,000 | 91,860,000 | 147,249,000 | 159,461,000 | 156,894,000 | 134,459,000 | ||||
| prepaid expenses and other current assets | 6,101,000 | 4,766,000 | 4,517,000 | 4,545,000 | 6,272,000 | 4,637,000 | 7,681,000 | 5,829,000 | 6,353,000 | 4,119,000 |
| total current assets | 235,307,000 | 251,699,000 | 202,168,000 | 223,913,000 | 228,732,000 | 248,502,000 | 270,099,000 | 286,553,000 | 300,276,000 | 115,883,000 |
| right-of-use assets – operating leases | 2,975,000 | 3,072,000 | 3,163,000 | 3,247,000 | 3,330,000 | 3,227,000 | 3,309,000 | |||
| property and equipment | 11,400,000 | 12,131,000 | 12,225,000 | 11,517,000 | 11,815,000 | 7,949,000 | 3,237,000 | 1,076,000 | 548,000 | 561,000 |
| other noncurrent assets | 1,614,000 | 2,124,000 | 2,117,000 | |||||||
| total assets | 251,296,000 | 269,026,000 | 219,673,000 | 238,677,000 | 243,877,000 | 259,678,000 | 276,645,000 | 287,629,000 | 300,824,000 | 118,709,000 |
| liabilities and stockholders' equity | ||||||||||
| current liabilities: | ||||||||||
| accounts payable | 1,239,000 | 1,547,000 | 1,611,000 | 2,892,000 | 4,722,000 | 3,485,000 | 6,019,000 | 3,899,000 | 3,049,000 | 3,111,000 |
| accrued and other current liabilities | 9,606,000 | 11,298,000 | 9,137,000 | 8,759,000 | 6,720,000 | 7,349,000 | 7,448,000 | 4,757,000 | 2,487,000 | 1,825,000 |
| current portion of operating lease liabilities | 2,185,000 | 2,169,000 | 2,153,000 | 2,137,000 | 1,591,000 | 1,061,000 | 530,000 | |||
| total current liabilities | 13,030,000 | 15,014,000 | 12,901,000 | 13,788,000 | 13,033,000 | 11,895,000 | 13,997,000 | 9,238,000 | 8,188,000 | 6,115,000 |
| operating lease liabilities, net of current portion | 5,886,000 | 6,272,000 | 6,645,000 | 6,658,000 | 5,089,000 | 5,235,000 | 2,964,000 | |||
| other noncurrent liabilities | 18,000 | 44,000 | 69,000 | 93,000 | 119,000 | 144,000 | 171,000 | 197,000 | 279,000 | |
| total liabilities | 18,916,000 | 21,304,000 | 19,590,000 | 20,515,000 | 18,215,000 | 17,249,000 | 17,105,000 | 9,409,000 | 8,385,000 | 6,394,000 |
| commitments and contingencies | ||||||||||
| stockholders' equity: | ||||||||||
| common stock | 7,000 | 7,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 2,000 |
| additional paid-in capital | 491,347,000 | 484,666,000 | 410,528,000 | 404,386,000 | 388,480,000 | 382,937,000 | 377,137,000 | 372,284,000 | 368,321,000 | 2,201,000 |
| accumulated other comprehensive loss | -48,000 | -66,000 | -63,000 | -403,000 | -609,000 | -275,000 | ||||
| accumulated deficit | -258,926,000 | -236,885,000 | -210,388,000 | -185,827,000 | -162,214,000 | -140,238,000 | -117,602,000 | -94,069,000 | -75,887,000 | -41,501,000 |
| total stockholders' equity | 232,380,000 | 247,722,000 | 200,083,000 | 218,162,000 | 225,662,000 | 242,429,000 | 259,540,000 | 278,220,000 | 292,439,000 | |
| total liabilities and stockholders' equity | 251,296,000 | 269,026,000 | 219,673,000 | 238,677,000 | 243,877,000 | 259,678,000 | ||||
| deferred revenue | 582,000 | 2,652,000 | 1,179,000 | |||||||
| cash | 261,357,000 | 279,082,000 | 291,271,000 | 110,585,000 | ||||||
| total liabilities, convertible preferred stock and stockholders' equity | 276,645,000 | 287,629,000 | 300,824,000 | |||||||
| liabilities, convertible preferred stock, and stockholders' equity | ||||||||||
| long-term convertible promissory note | ||||||||||
| embedded derivative liability | ||||||||||
| convertible preferred stock | 151,613,000 | |||||||||
| stockholders' equity | ||||||||||
| preferred stock, 0.0001 par value; 50,000,000 and no shares authorized at december 31, 2021 and 2020, respectively; no shares issued and outstanding at either december 31, 2021 or 2020 | ||||||||||
| preferred stock, 0.0001 par value; 50,000,000 and no shares authorized at september 30, 2021 and december 31, 2020, respectively; no shares issued and outstanding at september 30, 2021 and december 31, 2020 | ||||||||||
| deferred offering costs | 2,265,000 | |||||||||
| liabilities, convertible preferred stock, and stockholders' deficit | ||||||||||
| stockholders' deficit: | ||||||||||
| total stockholders' deficit | -39,298,000 | |||||||||
| total liabilities, convertible preferred stock and stockholders' deficit | 118,709,000 |
We provide you with 20 years of balance sheets for Icosavax stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Icosavax. Explore the full financial landscape of Icosavax stock with our expertly curated balance sheets.
The information provided in this report about Icosavax stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.